gef1 Antibody

What is GEF-H1 and where is it localized in cells?

GEF-H1 (Guanine Nucleotide Exchange Factor H1) is a microtubule-associated protein that localizes primarily to the cytoskeleton and Golgi apparatus. Immunofluorescent analysis using GEF-H1 antibodies in HeLa cells shows distinct localization patterns when cells are fixed in ice-cold methanol. The protein plays a crucial role in signaling pathways that are activated upon microtubule destabilization, particularly in immune cells such as dendritic cells . GEF-H1 functions as a key molecular switch that links microtubule dynamics to cellular signaling events that regulate immune activation and anti-tumor responses .

What applications are GEF-H1 antibodies suitable for?

GEF-H1 antibodies, such as the polyclonal rabbit antibody GTX125893, have been validated for multiple experimental applications:

• Western blot (WB)

• Immunocytochemistry/Immunofluorescence (ICC/IF)

• Immunohistochemistry on paraffin-embedded sections (IHC-P)

• Immunohistochemistry on frozen sections (IHC-Fr)

• Immunoprecipitation (IP)

These antibodies demonstrate reactivity across species including human, mouse, and rat samples, making them versatile tools for comparative studies across model organisms .

What dilutions are optimal for different GEF-H1 antibody applications?

Based on validated protocols, the following dilutions are recommended for GEF-H1 antibody GTX125893:

These dilutions have been optimized for specific experimental conditions and may require adjustment based on your particular research setup and detection systems .

How should I prepare samples for optimal GEF-H1 detection by immunofluorescence?

For effective immunofluorescent detection of GEF-H1:

• Fix cells in ice-cold methanol for 5 minutes

• Dilute GEF-H1 antibody (e.g., GTX125893) to 1:500

• For counterstaining nuclei, use Hoechst 33342

• For visualization, use a fluorescent secondary antibody against rabbit IgG

This protocol has been validated for detection of GEF-H1 at the cytoskeleton and Golgi apparatus with high specificity . The methanol fixation is particularly important as it preserves the microtubule structures to which GEF-H1 associates under normal conditions.

What protocol should I follow for Western blot detection of GEF-H1?

For optimal Western blot detection of GEF-H1:

• Prepare whole cell lysates (30 μg protein load recommended)

• Separate proteins using 5% SDS-PAGE (for standard applications) or 7.5% SDS-PAGE (for transfected samples)

• Transfer proteins to a membrane following standard protocols

• Block the membrane using appropriate blocking buffer

• Incubate with GEF-H1 antibody at 1:1000 dilution (or 1:4000 for transfected samples)

• Detect using HRP-conjugated anti-rabbit IgG antibody

• Develop using your preferred chemiluminescence method

This protocol has been successfully used with various cell lines including Neuro2A, GL261, NIH-3T3, BCL-1, Raw 264.7, and C2Cl2 .

What is the recommended protocol for immunohistochemical detection of GEF-H1?

For immunohistochemical analysis of GEF-H1 in tissue sections:

• Prepare frozen tissue sections (e.g., mouse cerebellum)

• Perform antigen retrieval using citrate buffer (pH 6.0) for 10 minutes

• Block non-specific binding sites with appropriate blocking buffer

• Incubate with GEF-H1 antibody diluted at 1:250

• For co-staining (if desired), use compatible antibodies such as NF-H antibody at 1:500

• Apply appropriate secondary antibodies

• Counterstain nuclei with DAPI or similar nuclear stain

• Mount and visualize under a fluorescence microscope

This protocol enables detection of GEF-H1 in specific tissue contexts while maintaining tissue architecture .

How does GEF-H1 contribute to dendritic cell activation and anti-tumor immunity?

GEF-H1 functions as a critical signaling molecule that links microtubule dynamics to immune activation. Research has identified GEF-H1 as an "alternate axis" in dendritic cell (DC) maturation that is specifically activated upon microtubule destabilization . This pathway is particularly significant because:

• When microtubules are destabilized (e.g., by certain chemotherapeutics), GEF-H1 is released from microtubules

• Activated GEF-H1 initiates signaling cascades that promote DC maturation

• Mature DCs enhance cross-presentation of antigens to CD8+ T cells

• This leads to effective priming of T cells against tumor antigens

• The resulting immune response contributes to tumor regression

This pathway represents an alternative to conventional pathogen recognition receptor (PRR)-mediated DC activation and is crucial for the anti-tumor effects of microtubule-destabilizing agents (MDAs) used in chemotherapy .

What transcriptional changes are mediated by GEF-H1 activation?

GEF-H1 activation upon microtubule destabilization induces significant transcriptional changes associated with innate immune responses. Gene set enrichment analyses (GSEAs) have revealed that GEF-H1 controls a microtubule destabilization-induced transcriptional signature including:

• TNF-α signaling pathway (187 genes; normalized enrichment score [NES] = 1.53)

• Inflammatory response (168 genes; NES = 1.42)

• IL-6-JAK-STAT3 signaling pathway (77 genes; NES = 1.40)

Further coexpression enrichment analysis identified 831 GEF-H1-dependent genes, with the top transcription factors belonging to the AP-1/ATF family . This transcriptional program resembles that activated during proinflammatory host defense responses, highlighting GEF-H1's role in connecting cytoskeletal dynamics to immune activation.

How can I study the kinetics of GEF-H1 activation upon microtubule destabilization?

To study GEF-H1 activation kinetics following microtubule destabilization:

• Treat cells with microtubule-destabilizing agents (e.g., nocodazole, colchicine)

• Collect samples at different time points post-treatment

• Perform subcellular fractionation to separate cytoskeletal and cytosolic fractions

• Analyze GEF-H1 localization by Western blot or immunofluorescence

• Assess downstream signaling by measuring activation of:

  • RhoA (a direct target of GEF-H1)

  • NF-κB pathway components

  • MAP kinase pathways (particularly p38 and JNK)

• Evaluate transcriptional changes using qPCR or RNA-seq focusing on the identified transcriptional signatures

For specific binding kinetics, techniques such as surface plasmon resonance (BIAcore) have been successfully employed to analyze antibody-antigen interactions with serial dilutions and defined flow rates (30 μL/min) .

How can I verify GEF-H1 antibody specificity for my research?

To confirm GEF-H1 antibody specificity:

• Perform validation using positive and negative controls:

  • Use cell lines known to express GEF-H1 (positive control)

  • Use GEF-H1 knockdown/knockout cells (negative control)

• For transfection studies, compare:

  • Non-transfected 293T cells (negative control)

  • GEF-H1-transfected 293T cells (positive control)

• Conduct peptide competition assays:

  • Pre-incubate the antibody with the immunizing peptide

  • Compare staining patterns with and without peptide competition

• Validate across multiple applications (Western blot, IF, IHC) to ensure consistent detection patterns

How can I quantify GEF-H1 expression levels with high precision?

For precise quantification of GEF-H1 expression:

• Western blot quantification:

  • Use appropriate loading controls (β-actin, GAPDH)

  • Apply densitometry analysis with standard curves

  • Normalize GEF-H1 signals to loading controls

• For absolute quantification:

  • Consider adapting absolute quantitation methods used for antibody measurements in clinical samples

  • Use purified recombinant GEF-H1 protein to create standard curves

  • Apply mass spectrometry-based approaches for protein quantification

• For mRNA expression:

  • Use quantitative RT-PCR with validated primers

  • Apply the ΔΔCt method with appropriate reference genes

• For single-cell analysis:

  • Consider flow cytometry with validated antibodies

  • Use imaging cytometry for combined localization and expression data

What controls should I include when studying GEF-H1 in microtubule destabilization experiments?

When investigating GEF-H1 in the context of microtubule destabilization:

• Include treatment controls:

  • Vehicle control (DMSO or appropriate solvent)

  • Microtubule stabilizing agent (e.g., taxol) as a contrasting condition

  • Different concentrations of microtubule-destabilizing agents to assess dose-dependency

• Include genetic controls:

  • GEF-H1 siRNA/shRNA knockdown cells

  • CRISPR/Cas9 GEF-H1 knockout cells

  • Rescue experiments with wild-type GEF-H1 expression

• Include temporal controls:

  • Time course experiments to capture the dynamics of GEF-H1 activation

  • Recovery experiments where microtubule-destabilizing agents are washed out

• For immune activation studies:

  • Compare GEF-H1-dependent pathways with conventional PRR-activated pathways

  • Use dendritic cells from GEF-H1 knockout mice versus wild-type mice

This comprehensive control strategy will help establish causality between microtubule destabilization, GEF-H1 activation, and downstream immune responses.

How is GEF-H1 involved in the development of new antibody screening technologies?

While not directly related to GEF-H1 itself, innovations in antibody technology development provide insights for GEF-H1 research. New approaches for genotype-phenotype linked antibody screening employ:

• Golden Gate-based dual-expression vector systems for rapid antibody cloning and expression

• In-vivo expression of membrane-bound antibodies

• Single-step procedures that enable enrichment of antigen-specific, high-affinity antibodies by flow cytometry

• Next-generation sequencing (NGS) technology paired with functional screening

These methodologies could potentially be applied to develop higher specificity GEF-H1 antibodies or to study GEF-H1 binding partners through techniques like phage display or yeast two-hybrid screening.

What is the relationship between GEF-H1 and cancer therapy response?

GEF-H1 plays a critical role in anti-tumor immunity particularly in the context of microtubule-targeting chemotherapeutics:

• GEF-H1 activation in dendritic cells promotes protective anti-tumor immunity

• Microtubule-destabilizing chemotherapeutics induce DC maturation through GEF-H1 activation

• This leads to effective priming of CD8+ T cells against tumor antigens

• GEF-H1 signaling is critical for the anti-tumor immunity effects of microtubule-targeting chemotherapy

Understanding this pathway provides insight into how certain chemotherapeutics may elicit immune responses beyond their direct cytotoxic effects, potentially informing combination therapies with immune checkpoint inhibitors or other immunomodulatory approaches.

How can advanced microscopy techniques enhance the study of GEF-H1 dynamics?

To investigate GEF-H1 dynamics at higher resolution:

• Consider super-resolution microscopy techniques:

  • Structured illumination microscopy (SIM)

  • Stimulated emission depletion (STED) microscopy

  • Stochastic optical reconstruction microscopy (STORM)

• For live-cell imaging:

  • Generate GEF-H1-fluorescent protein fusions (e.g., GEF-H1-GFP)

  • Use spinning disk confocal microscopy for rapid acquisition

  • Consider light sheet microscopy for reduced phototoxicity

• For protein interaction studies:

  • Förster resonance energy transfer (FRET)

  • Fluorescence lifetime imaging microscopy (FLIM)

  • Proximity ligation assay (PLA) with GEF-H1 antibodies

These advanced imaging approaches could reveal new insights into how GEF-H1 transitions between microtubule-bound and active states during cellular responses to various stimuli.